Loading...

Dicerna Pharmaceuticals

Nasdaq:DRNA
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
DRNA
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The last earnings update was 48 days ago. More info.


Add to Portfolio Compare Print
  • Dicerna Pharmaceuticals has significant price volatility in the past 3 months.
DRNA Share Price and Events
7 Day Returns
2.5%
NasdaqGS:DRNA
-0.8%
US Biotechs
-0.4%
US Market
1 Year Returns
35.1%
NasdaqGS:DRNA
-3.7%
US Biotechs
4.3%
US Market
DRNA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Dicerna Pharmaceuticals (DRNA) 2.5% 27.1% 8.1% 35.1% 427.7% -26.3%
US Biotechs -0.8% 2% -1.7% -3.7% 18% 5.6%
US Market -0.4% 2.8% 2.7% 4.3% 40.9% 38.2%
1 Year Return vs Industry and Market
  • DRNA outperformed the Biotechs industry which returned -3.7% over the past year.
  • DRNA outperformed the Market in United States of America which returned 4.3% over the past year.
Price Volatility
DRNA
Industry
5yr Volatility vs Market
Related Companies

DRNA Value

 Is Dicerna Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Dicerna Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $15.83.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Dicerna Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Dicerna Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:DRNA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-1.66
NasdaqGS:DRNA Share Price ** NasdaqGS (2019-06-26) in USD $15.83
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 18.55x
United States of America Market PE Ratio Median Figure of 3,094 Publicly-Listed Companies 17.77x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Dicerna Pharmaceuticals.

NasdaqGS:DRNA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:DRNA Share Price ÷ EPS (both in USD)

= 15.83 ÷ -1.66

-9.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dicerna Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Dicerna Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Dicerna Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGS:DRNA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-4.2%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.01x
United States of America Market PEG Ratio Median Figure of 2,133 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Dicerna Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Dicerna Pharmaceuticals's assets?
Raw Data
NasdaqGS:DRNA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.63
NasdaqGS:DRNA Share Price * NasdaqGS (2019-06-26) in USD $15.83
United States of America Biotechs Industry PB Ratio Median Figure of 431 Publicly-Listed Biotechs Companies 3x
United States of America Market PB Ratio Median Figure of 5,255 Publicly-Listed Companies 1.78x
NasdaqGS:DRNA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:DRNA Share Price ÷ Book Value per Share (both in USD)

= 15.83 ÷ 2.63

6.02x

* Primary Listing of Dicerna Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dicerna Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Dicerna Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Dicerna Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

DRNA Future Performance

 How is Dicerna Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-4.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Dicerna Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Dicerna Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Dicerna Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Dicerna Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:DRNA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:DRNA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -4.2%
NasdaqGS:DRNA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 23%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:DRNA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:DRNA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 100 108 -88 4
2022-12-31 43 17 -134 4
2021-12-31 61 -32 -112 4
2020-12-31 50 -102 -97 6
2019-12-31 41 -22 -88 6
NasdaqGS:DRNA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 8 107 -99
2018-12-31 6 18 -89
2018-09-30 6 -49 -93
2018-06-30 4 -51 -93
2018-03-31 3 -49 -82
2017-12-31 1 -45 -80
2017-09-30 0 -51 -71
2017-06-30 0 -50 -66
2017-03-31 0 -47 -58
2016-12-31 -49 -60
2016-09-30 0 -50 -61
2016-06-30 0 -52 -64

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Dicerna Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Dicerna Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:DRNA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Dicerna Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:DRNA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -1.14 -0.20 -2.09 4.00
2022-12-31 -1.71 -1.04 -2.57 4.00
2021-12-31 -1.46 -0.64 -2.60 6.00
2020-12-31 -1.42 -0.79 -2.50 8.00
2019-12-31 -1.39 -0.69 -2.08 8.00
NasdaqGS:DRNA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -1.66
2018-12-31 -1.60
2018-09-30 -2.02
2018-06-30 -2.48
2018-03-31 -2.75
2017-12-31 -3.66
2017-09-30 -3.43
2017-06-30 -3.20
2017-03-31 -2.80
2016-12-31 -2.87
2016-09-30 -2.84
2016-06-30 -2.97

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Dicerna Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Dicerna Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Dicerna Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

DRNA Past Performance

  How has Dicerna Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Dicerna Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Dicerna Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Dicerna Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Dicerna Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Dicerna Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Dicerna Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:DRNA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 7.74 -99.43 27.03
2018-12-31 6.18 -88.85 21.69
2018-09-30 5.67 -93.20 18.96
2018-06-30 4.12 -93.32 17.75
2018-03-31 2.58 -81.67 15.68
2017-12-31 1.03 -80.29 16.84
2017-09-30 0.13 -71.36 17.20
2017-06-30 0.30 -66.39 17.40
2017-03-31 0.30 -58.02 19.36
2016-12-31 -59.51 15.43
2016-09-30 0.16 -61.13 17.90
2016-06-30 0.00 -63.89 18.42
2016-03-31 0.18 -64.45 18.28
2015-12-31 0.18 -62.84 19.24
2015-09-30 0.18 -61.79 19.53
2015-06-30 0.18 -56.04 18.40
2015-03-31 -51.22 18.25
2014-12-31 -48.14 15.65
2014-09-30 -40.28 13.18
2014-06-30 -33.63 10.76
2014-03-31 -27.08 7.53
2013-12-31 -20.91 5.82
2013-09-30 6.25 -13.69 4.65
2013-06-30 6.51 -14.09 4.47
2013-03-31 6.76 -14.16 4.58
2012-12-31 7.02 -14.22 4.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Dicerna Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Dicerna Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Dicerna Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Dicerna Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Dicerna Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

DRNA Health

 How is Dicerna Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Dicerna Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Dicerna Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Dicerna Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Dicerna Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Dicerna Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Dicerna Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGS:DRNA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 179.63 0.00 371.20
2018-12-31 200.69 0.00 302.63
2018-09-30 156.38 0.00 180.38
2018-06-30 64.58 8.90 82.30
2018-03-31 87.89 0.00 97.82
2017-12-31 101.09 0.00 113.68
2017-09-30 72.20 0.00 75.92
2017-06-30 85.14 0.00 88.73
2017-03-31 29.09 0.00 32.88
2016-12-31 41.21 0.00 45.87
2016-09-30 53.13 0.00 57.55
2016-06-30 64.97 0.00 69.19
2016-03-31 78.18 0.00 80.65
2015-12-31 91.02 0.00 94.61
2015-09-30 104.28 0.00 94.04
2015-06-30 118.68 0.00 95.01
2015-03-31 86.73 0.00 87.67
2014-12-31 98.34 0.00 96.12
2014-09-30 110.82 0.00 92.89
2014-06-30 120.20 0.00 100.26
2014-03-31 129.33 3.79 133.79
2013-12-31 41.86 4.85 46.60
2013-09-30 48.11 5.88 54.71
2013-06-30 -7.47 9.56 1.84
2013-03-31 -0.14 8.80 3.67
2012-12-31 -0.14 8.80 3.67
  • Dicerna Pharmaceuticals has no debt.
  • Dicerna Pharmaceuticals has no debt compared to 5 years ago when it was 2.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Dicerna Pharmaceuticals has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Dicerna Pharmaceuticals has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -55.4% per year.
X
Financial health checks
We assess Dicerna Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Dicerna Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

DRNA Dividends

 What is Dicerna Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Dicerna Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Dicerna Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Dicerna Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Dicerna Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:DRNA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2012 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:DRNA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Dicerna Pharmaceuticals has not reported any payouts.
  • Unable to verify if Dicerna Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Dicerna Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Dicerna Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Dicerna Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Dicerna Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Dicerna Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Dicerna Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

DRNA Management

 What is the CEO of Dicerna Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Douglas Fambrough
COMPENSATION $2,497,561
AGE 49
TENURE AS CEO 9.1 years
CEO Bio

Dr. Douglas M. Fambrough, III, Ph.D., is a Co-Founder Dicerna Pharmaceuticals, Inc. and has been its Chief Executive Officer and President since May 2010. Dr. Fambrough served as a Venture Partner at Oxford Bioscience Partners and focused his investments on innovative life science technology companies. Dr. Fambrough joined the Oxford Bioscience Partners in 1999 as an Associate and became a Principal in 2001. He became a Partner in 2005 and served as its General Partner from 2007 to 2010. Previously, Dr. Fambrough spent ten years in academic research as a Genomic Scientist, most recently at the Whitehead/MIT Center for Genome Research. He served as the Chairman of Dicerna Pharmaceuticals, Inc. until July 2009. He has been Director of Dicerna pharmaceuticals, Inc since April 2007. He serves as a Director of Endogeny Bio, Solexa and Sirna Therapeutics, Inc. Dr. Fambrough also represented Oxford as a Board Observer at RibX Pharmaceuticals, Xencor, Inc., Cambrios Technologies, Xantos Biomedicine AG and Avalon Pharmaceuticals. He served as a Director of Solstice Neurosciences and Xencor, Inc. He graduated from Cornell University and obtained a Ph.D. in Genetics from the University of California, Berkeley.

CEO Compensation
  • Douglas's compensation has increased whilst company is loss making.
  • Douglas's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Dicerna Pharmaceuticals management team in years:

2.8
Average Tenure
60
Average Age
  • The tenure for the Dicerna Pharmaceuticals management team is about average.
Management Team

Douglas Fambrough

TITLE
Co-Founder
COMPENSATION
$2M
AGE
49
TENURE
9.1 yrs

Jack Green

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
64
TENURE
3.2 yrs

Bob Brown

TITLE
Senior VP & Chief Scientific Officer
COMPENSATION
$1M
AGE
53
TENURE
7.4 yrs

Mark Behlke

TITLE
Co-Founder & Member of Scientific Advisory Board

John Rossi

TITLE
Co-Founder & Chairman of Scientific Advisory Board
AGE
71

David Miller

TITLE
Senior Vice President of Corporate Operations & Alliance Management
TENURE
2.5 yrs

Regina Paglia

TITLE
Senior Vice President of Human Resources
TENURE
0.3 yrs

Jim Weissman

TITLE
Chief Business Officer
COMPENSATION
$1M
AGE
56
TENURE
7.4 yrs

Jennifer Lockridge

TITLE
Senior Vice President of Program Development
TENURE
1.4 yrs

Ralf Rosskamp

TITLE
Chief Medical Officer
COMPENSATION
$953K
AGE
65
TENURE
2 yrs
Board of Directors Tenure

Average tenure and age of the Dicerna Pharmaceuticals board of directors in years:

10.7
Average Tenure
63
Average Age
  • The average tenure for the Dicerna Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

J. Buchi

TITLE
Chairman of the Board
COMPENSATION
$273K
AGE
63
TENURE
0.4 yrs

Douglas Fambrough

TITLE
Co-Founder
COMPENSATION
$2M
AGE
49
TENURE
12.2 yrs

Mark Behlke

TITLE
Co-Founder & Member of Scientific Advisory Board

John Rossi

TITLE
Co-Founder & Chairman of Scientific Advisory Board
AGE
71
TENURE
10.7 yrs

Martin Freed

TITLE
Independent Director
COMPENSATION
$266K
AGE
57
TENURE
3 yrs

Adam Koppel

TITLE
Director
COMPENSATION
$260K
AGE
48
TENURE
2.2 yrs

Steve Hoffman

TITLE
Director
COMPENSATION
$272K
AGE
64
TENURE
11.6 yrs

Frank McCormick

TITLE
Member of Scientific Advisory Board
AGE
68
TENURE
10.7 yrs

Dennis Langer

TITLE
Director
COMPENSATION
$265K
AGE
66
TENURE
11.6 yrs

Peter Kolchinsky

TITLE
Director
COMPENSATION
$264K
AGE
41
TENURE
5.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
31. May 19 Sell Bain Capital, LP Company 29. May 19 29. May 19 -1,600,000 $12.50 $-20,000,000
06. Nov 18 Sell Domain Associates, L.L.C. Company 02. Nov 18 06. Nov 18 -335,000 $14.16 $-4,464,113
05. Nov 18 Sell Domain Associates, L.L.C. Company 30. Oct 18 01. Nov 18 -565,000 $14.31 $-7,717,550
X
Management checks
We assess Dicerna Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Dicerna Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

DRNA News

Simply Wall St News

Does Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) CEO Salary Compare Well With Others?

View our latest analysis for Dicerna Pharmaceuticals How Does Douglas Fambrough's Compensation Compare With Similar Sized Companies? … The graphic below shows how CEO compensation at Dicerna Pharmaceuticals has changed from year to year. … If you think CEO compensation levels are interesting you will probably really like this free visualization of insider trading at Dicerna Pharmaceuticals.

Simply Wall St -

Did You Miss Dicerna Pharmaceuticals's (NASDAQ:DRNA) Impressive 194% Share Price Gain?

Dicerna Pharmaceuticals isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth. … Dicerna Pharmaceuticals's revenue trended up 110% each year over three years.

Simply Wall St -

Will Dicerna Pharmaceuticals, Inc.'s (NASDAQ:DRNA) Earnings Grow In The Years Ahead?

The latest earnings update Dicerna Pharmaceuticals, Inc. … (NASDAQ:DRNA) released in December 2018 … company earnings became less negative compared to the previous year's level

Simply Wall St -

Interested In Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)? Here's How It Performed Recently

Today I will assess DRNA's recent performance announced on 31 March 2018 and compare these figures to its long-term trend and industry movements. … Was DRNA's recent earnings decline worse than the long-term trend and the industry. … DRNA is loss-making, with the most recent trailing twelve-month earnings of -US$81.52m (from 31 March 2018), which compared to last year has become.

Simply Wall St -

Interested In Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)? Here's How It Performed Recently

When Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its most recent earnings update (31 December 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … For Dicerna Pharmaceuticals, its latest earnings (trailing twelve month) is -US$80.14M, which, relative to the previous year's level, has become more negative. … Dicerna Pharmaceuticals's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story.

Simply Wall St -

With A -16.74% Earnings Drop Lately, Did Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Underperform Its Industry?

In this article, I will take a look at Dicerna Pharmaceuticals Inc's (NASDAQ:DRNA) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past few years, along with how the rest of DRNA's industry performed. … Check out our latest analysis for Dicerna Pharmaceuticals Was DRNA's recent earnings decline indicative of a tough track record? … For Dicerna Pharmaceuticals, its most recent earnings (trailing twelve month) is -$71.4M, which compared to last year’s level, has become more negative.

Simply Wall St -

What Do Analysts Think About Dicerna Pharmaceuticals Inc's (NASDAQ:DRNA) Earnings Trajectory?

The latest earnings release Dicerna Pharmaceuticals Inc's (NASDAQ:DRNA) announced in September 2017 signalled company earnings became less negative compared to the previous year's level as a result of recent tailwinds Today I want to provide a brief commentary on how market analysts predict Dicerna Pharmaceuticals's earnings growth outlook over the next few years and whether the future looks brighter. … View our latest analysis for Dicerna Pharmaceuticals Analysts' expectations for next year seems pessimistic, with earnings becoming even more negative, arriving at $-69.7M in 2018. … This means, we can presume Dicerna Pharmaceuticals will grow its earnings by 12.67% every year for the next few years.

Simply Wall St -

Should You Buy Dicerna Pharmaceuticals Inc (DRNA)?

DRNA is currently overpriced based on my relative valuation model. … Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at DRNA future expectations. … If you believe DRNA is currently trading above its peers, selling high and buying it back up again when its price falls towards its real value can be profitable.

Simply Wall St -

DRNA Company Info

Description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company’s development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Details
Name: Dicerna Pharmaceuticals, Inc.
DRNA
Exchange: NasdaqGS
Founded: 2006
$1,081,568,587
68,323,979
Website: http://www.dicerna.com
Address: Dicerna Pharmaceuticals, Inc.
87 Cambridgepark Drive,
Cambridge,
Massachusetts, 02140,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS DRNA Common Stock Nasdaq Global Select US USD 30. Jan 2014
DB DPL Common Stock Deutsche Boerse AG DE EUR 30. Jan 2014
Number of employees
Current staff
Staff numbers
78
Dicerna Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/27 00:41
End of day share price update: 2019/06/26 00:00
Last estimates confirmation: 2019/05/25
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.